The expression of BIRC1 and BIRC5 significantly varied across LUAD stages, and the expression of BIRC5 significantly varied across LUSC stages (Figure 2), suggesting that these IAPs may serve as potential biomarkers for diagnosis and cancer staging in NSCLC patients. Here, NAIP is linked to non-small cell lung carcinoma.